"Designing Growth Strategies is in our DNA"

Diabetic Retinopathy Treatment Market Size, Share and Global Trend By Diabetic Retinopathy Type (Non-Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy), By Treatment Type (Anti-Vascular Endothelial Growth Factor (VEGF) Drug, Laser Surgery, Vitrectomy, Intraocular Steroid Injection), By End User (Hospitals, Ophthalmic Centres, Ambulatory Surgery Centres, Others) and Geography Forecast till 2026

Region : Global | Report ID: FBI101153 | Status : Ongoing

 

KEY MARKET INSIGHTS

Diabetic retinopathy is a medical disorder, resulting from the complications of diabetes mellitus and is also one of the leading cause of blindness. Diabetic retinopathy is determined by the type of diabetes the individual is diagnosed with, amount of time that the individual has diabetes and the level to which the blood sugar is controlled. The symptoms of diabetic retinopathy include very mild to no symptoms at the beginning of the condition, blurred and fluctuating vision, impairment of color vision, eventually leading to blindness.

Management of diabetes is critical towards the prevention and successful treatment of diabetic retinopathy because excessive sugar in the blood can lead to the blocking of the tiny blood vessels nourishing the retina, cutting off the blood supply. This results in the formation of new blood vessels which are not perfectly developed, leading to being susceptible to leaks easily.

To gain extensive insights into the market, Request for Customization

Some of the associated complications of diabetic retinopathy include blindness, cataracts, vitreous hemorrhage, glaucoma, and retinal detachment. Diabetic retinopathy is highly treatable, even individuals diagnosed with advanced diabetic retinopathy have an estimated 95% chance of retaining their vision before the retina is permanently damaged.


The global diabetic retinopathy treatment market is anticipated to grow at faster CAGR, owing to a number of factors such as the increasing prevalence of diabetic retinopathy, increasing prevalence of diabetes of all types, and increasing incidence of associated complications such as blindness.

Moreover, increasing research advances in treatment and prevention and rising demand for preventive medical care through regular eye examinations is expected to boost the growth of the global diabetic retinopathy market during the forecast period. According to research conducted by the Centres for Disease Control and Preventions (CDC), in 2017, an estimated 4.2 million adults were suffering from diabetic retinopathy in the U.S.


Some of the factors limiting the growth of the global diabetic retinopathy treatment market are the negligence of people to the symptoms of diabetic retinopathy, poor management of treatment of diabetic retinopathy and increased risk of the associated side effects of the treatment options.


Key Players Covered


Some of the major companies that are present in the global diabetic retinopathy treatment market are F. Hoffmann-La Roche Ltd, Alimera Sciences, Abbott, Novartis AG, Regeneron Pharmaceuticals, Inc., Pfizer Inc., Bayer AG, and Oxurion NV, and others.


SEGMENTATION


























SEGMENTATION


 DETAILS

By Diabetic Retinopathy Type



· Non-Proliferative Diabetic Retinopathy


· Proliferative Diabetic Retinopathy 



By Treatment Type



· Anti-Vascular Endothelial Growth Factor (VEGF) Drug


· Laser Surgery


· Vitrectomy


· Intraocular Steroid Injection



By End User



· Hospitals


· Ophthalmic Centres


· Ambulatory Surgery Centres


· Others



By Geography



· North America (USA and Canada)


· Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)


· Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)


· Latin America (Brazil, Mexico and Rest of Latin America)


· Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)



 


Among the segmentation, anti-vascular endothelial growth factor (VEGF) drug in the treatment type segment is expected to hold a considerable share in the market during the forecast period. Proven significance in the treatment of diabetic retinopathy in clinical trials is expected to boost the adoption of anti-vascular endothelial growth factor (vegf) drug by 2026.


Key Insights 



  • The regulatory scenario for key countries

  • Pipeline Analysis

  • Epidemics of Diabetic Retinopathy – Key Countries

  • New Product Launches by Key Players

  • Recent industry developments such as partnerships, mergers, and acquisitions


Regional Analysis


North America is expected to account for the largest share in the global diabetic retinopathy market due to the increasing prevalence of diabetic retinopathy and associated complications, rise in the incidence of diabetes, and increasing demand for preventive care. Additionally, increasing awareness regarding regular eye examinations amongst populations, established healthcare systems, and access to advanced technologies is anticipated to boost the growth of the diabetic retinopathy treatment market in North America by 2026. The Asia Pacific expected to be is the fastest emerging market due to the rapidly increasing prevalence of diabetic retinopathy coupled with increasing disposable incomes and developing healthcare systems in emerging economies.


Key Industry Developments




  • In July 2018, Government of Australia announced funding provision for Nation Diabetes Eye Screening Program. The program is Australia’s first ever program to diagnose and treat people suffering from diabetic retinopathy across the Australia.
  • In April 2018, FDA approved first ever artificial intelligence based diagnostic system designed and developed by IDx Technologies Inc. The newly developed system enables to detect diabetic retinopathy amongst patients during regular clinic visits.
  • In April 2017, FDA approved Lucentis (ranibizumab injection) 0.3 mg, developed by Genentech, Inc., subsidiary of Roche group, for the treatment of diabetic retinopathy on monthly basis. It is the only FDA approved drug available for all types of diabetic retinopathy treatments.

Diabetic Retinopathy Treatment Market Size, Share and Global Industry Trend Forecast till 2026
  • Ongoing
  • 2019
  • 2016-2018

    CHOOSE LICENSE TYPE

  • 4850
    6850
    8850

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Healthcare Clients

lpsos
Logo_Merck_KGaA_2015
Natus-Medical
Ge-Healthcare
DUPONT

Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.
X